Short answer
Medpace Holdings Inc (MEDP) filed its Q3 2026 10-Q quarterly report on Oct 22, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $716M (up 8.5% year over year) with net income of $137M.
Q3 2026 key financials · XBRL
- Revenue
- $716M
- +8.5% YoY · +1.2% QoQ
- Net income
- $137M
- +23.7% YoY · +13.3% QoQ
- Operating margin
- 23.1%
- EPS (diluted)
- $4.84
- +25.7% YoY · +13.9% QoQ
Source: XBRL data from the Medpace Holdings Inc (MEDP) Q3 2026 10-Q on SEC EDGAR. USD.
Medpace Holdings Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $716.0M, up 8.5% YoY from $659.9M, driven by Metabolic, Oncology and CNS
- Operating margin 23.1% vs 21.5% YoY, based on operating income of $165.5M and revenue of $716.0M
- Best-performing therapeutic areas: Metabolic, Oncology and CNS, with no individual revenue figures disclosed
- Cash $705.3M vs $497.0M at December 31, 2025, operating cash flow $530.4M for nine months
- Nine-month share repurchases $294.7M, with $527.0M authorization remaining; new $1.0B authorization approved October 20, 2026
Risk Factors
- No significant changes from the December 31, 2025 Form 10-K risk factors
- Carried-forward risks include operational, regulatory, competitive, market, and financial exposures disclosed in the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Medpace Holdings Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.